HanchorBio Inc. (TPE:7827)

Market Cap	18.97B +116.9%
Revenue (ttm)	321.77M
Net Income	-572.58M
EPS	-4.46
Shares Out	139.97M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	295,297
Open	135.50
Previous Close	138.00
Day's Range	125.50 - 136.00
52-Week Range	63.70 - 187.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About HanchorBio

HanchorBio Inc. engages in the research and development of new anti-cancer drugs in Hong Kong and Mainland China. The companys product pipeline consists of HCB101, which is in phase II clinical trial to treat head and neck cancer, triple-negative breast cancer, gastric cancer, colorectal cancer, and small cell lung cancer; HCB301, which is in phase I clinical trial for the treatment of hematologic malignancies, head and neck cancer, and solid tumors; and HCB303, which is in preclinical trial to treat hematologic malignancies, head and neck canc...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 127
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 7827

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 30, 2026

Data Sources Report a data error